GSA Capital Partners LLP Acquires Shares of 3,559 Becton, Dickinson and Company $BDX

GSA Capital Partners LLP bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 3,559 shares of the medical instruments supplier’s stock, valued at approximately $539,000.

Several other institutional investors have also modified their holdings of the business. Brighton Jones LLC raised its position in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. Empowered Funds LLC grew its position in shares of Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after buying an additional 1,354 shares in the last quarter. United Bank increased its stake in shares of Becton, Dickinson and Company by 23.9% in the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after buying an additional 993 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Becton, Dickinson and Company by 365.1% in the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after buying an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC raised its holdings in Becton, Dickinson and Company by 34.7% in the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock valued at $4,048,000 after acquiring an additional 6,058 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. This represents a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,779 shares of company stock worth $1,974,669 over the last quarter. 0.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Piper Sandler raised their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. TD Cowen upped their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Bank of America reduced their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Wells Fargo & Company lifted their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Finally, Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $185.67.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $187.79 on Friday. The stock has a market capitalization of $51.74 billion, a PE ratio of 56.56, a price-to-earnings-growth ratio of 13.22 and a beta of 0.19. The business’s fifty day moving average price is $160.66 and its 200 day moving average price is $160.91. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $190.01.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.